Preclinical studies have played a key role in defining NUT midline carcinoma, multiple myeloma, and acute myeloid leukemia as diseases leveraged for sensitivity to bromodomain inhibition. Here, we provide a mechanistic rationale for the clinical study of bromodomain inhibitors in non-small cell lung cancer (NSCLC). Using validated models of NSCLC in vitro and in vivo, we provide experimental evidence that the prototype BET bromodomain inhibitor, JQ1, exerts remarkable anti-tumor efficacy in a subset of NSCLC cells harboring KRAS mutation. Sensitivity to bromodomain inhibition is highly influenced by LKB1 mutation status, as Kras/Lkb1 mutant tumor models are comparatively more resistant. Furthermore, the series of in vivo experiments using genetically engineered mouse lung cancer models described in this manuscript Furthermore, we evaluated JQ1 in transgenic mouse lung cancer models expressing mutant kras or concurrent mutant kras and lkb1. Effects of bromodomain inhibition on transcriptional pathways were explored and validated by expression analysis.
TRANSLATIONAL RELEVANCE
Preclinical studies have played a key role in defining NUT midline carcinoma, multiple myeloma, and acute myeloid leukemia as diseases leveraged for sensitivity to bromodomain inhibition. Here, we provide a mechanistic rationale for the clinical study of bromodomain inhibitors in non-small cell lung cancer (NSCLC). Using validated models of NSCLC in vitro and in vivo, we provide experimental evidence that the prototype BET bromodomain inhibitor, JQ1, exerts remarkable anti-tumor efficacy in a subset of NSCLC cells harboring KRAS mutation. Sensitivity to bromodomain inhibition is highly influenced by LKB1 mutation status, as Kras/Lkb1 mutant tumor models are comparatively more resistant. Furthermore, the series of in vivo experiments using genetically engineered mouse lung cancer models described in this manuscript confirmed that single-agent bromodomain inhibition prompts bona fide tumor regression in mutant Kras mouse lung cancers. Consistent with cultured human cell lines, Kras/Lkb1 mutant tumors were less responsive to the bromodomain inhibitor. Sensitivity both in vitro and in vivo is mediated by down-regulation of MYC, a known master regulatory transcription factor downstream of the KRAS signaling pathway. The data presented in this manuscript identifies a genetically-defined cohort of patients unlikely to respond to JQ1 treatment, guiding patient selection in early-stage cancer clinical trials.
INTRODUCTION
Approximately 15 -30% of human non-small cell lung cancer (NSCLC) patients harbor an oncogenic KRAS mutation associated with resistance to conventional treatment regimens (1). Oncogenic activation of kras in the murine lung compartment produces adenocarcinoma, and several human lung cancer cell lines harboring mutant KRAS are dependent on KRAS activity for survival (2) (3) (4) ; therefore, oncogenic mutant KRAS is a highly attractive therapeutic target in NSCLC. However, targeting mutant KRAS with small molecule inhibitors has not proven successful (1).
KRAS is a strong activator of mitogen-activated protein kinase (MAPK) and phosphatydilinositol-3-kinase (PI3K) pathways, which together confer oncogene addiction (5) . In a murine lung adenocarcinoma model driven by mutant Kras, the concurrent inhibition of MAPK and PI3K pathways demonstrates significant tumor regression (6) . Based on these preclinical data, this strategy has translated to phase I clinical trials for NSCLC patients with KRAS mutation. Although exact mechanisms of cell death remain elusive, several reports suggest that the inhibition of MAPK and PI3K pathways converges at the level of transcription factor MYC (7) . The inhibition of KRASdependent MAPK and PI3K pathways results in the dephosphorylation of MYC at Serine-62 and phosphorylation at Threonine-58 (7, 8) . These events contribute to rapid degradation of MYC in a proteasome-dependent manner. Several lines of evidence support a critical function for MYC in enforcing the transcriptional growth pathway downstream of KRAS (9) . Notably, research by Gerard Evan and colleagues has established the dependence of KRAS-mutated NSCLC on MYC by pharmacologic induction of a dominant-negative genetic construct, called OmoMyc (10, 11) . These 6 observations establish a pressing rationale to test therapies targeting the Myc transcriptional signaling network in KRAS mutant NSCLC models in vitro and in vivo.
MYC is a master regulatory transcription factor governing cellular growth, and deregulation of MYC in cancer contributes to proliferation, metabolic adaptation, tumorigenesis and resistance to apoptosis. Indeed, amplification of MYC is one of the most common genetic alterations in cancer genomes (12) . MYC is a basic helix-loophelix leucine zipper transcriptional activator and amplifier (13) , which localizes to E-box binding sites at promoter and enhancer regulatory regions, as a heterodimer with Max.
To date, efforts to create drug-like, direct-acting inhibitors of MYC have not been successful. This perhaps is due to the difficulty of targeting the extended protein-protein interface defined by the heterodimer and the absence of a defined ligand-binding domain (14) . We have therefore undertaken an effort to impede MYC-dependent transcriptional signaling by optimizing and characterizing inhibitors of putative MYC coactivator proteins. Recently, we reported MYC-specific inhibitory activity of a highly selective inhibitor of BET bromodomains, JQ1, in models of multiple myeloma and acute leukemia (15, 16) . These studies demonstrated selective inhibition of growth-and metabolism-associated transcriptional pathways characteristic of MYC function, without overt effects on other key transcriptional complexes such as AP-1 and NF-κB. In an index study of BET bromodomain inhibition, we observed marked efficacy of JQ1 in models of the rare and lethal, t(15;19) subset of squamous adenocarcinoma of the head, neck and lung known as NUT midline carcinoma (17, 18) . Recent research from our group has identified an inhibitory effect of BET inhibition on N-MYC function as well, in translational models of neuroblastoma (19) .
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Based on the rationale that BET bromodomain inhibition may confer MYCspecific anti-proliferative effects downstream of KRAS signaling, we undertook a detailed study of JQ1 in NSCLC. We have recently demonstrated that geneticallyengineered mouse (GEM) models provide valuable platforms to test clinically-relevant hypotheses, which can be immediately extended to the design and implementation of human clinical trials (20) . To evaluate the therapeutic efficacy of JQ1 in a common, clinically relevant subset of NSCLC, we performed genetic and functional analyses to assess the impact of JQ1 treatment in mouse lung tumors. 
MATERIALS AND METHODS:
Cell lines and viability assays NSCLC cell lines were obtained from the American Type Culture Collection (ATCC) and were maintained as specified. The cells lines were tested by a certified third party laboratory for authenticity (See Supplementary Methods). JQ1 was dissolved in cell culture grade dimethylsulfoxide (DMSO; Sigma). Cell viability assay was performed as described previously (21) , and as detailed in Supplementary Methods.
Western blot analysis
Lysate preparation and Western blot were performed as described previously (22) . Detailed methods and a list of antibodies used are available in Supplementary Methods.
Luminex Assay
Luminex-based multi-bead assays were carried out as described previously (21) .
Briefly, quantification of MYC and apoptosis were assayed using the Milliplex Pluripotent Stem Cell Assay and Milliplex Human Apoptosis Assay, respectively (Millipore).
shRNA constructs, lentiviral infection, and siRNA transfection.
pLKO.1 short hairpin RNA (shRNA) constructs designed by the Harvard RNAi consortium and siRNA (Thermo) was used as described previously (22) . shRNA sequences and procedures are provided in Supplementary Methods. 
Analysis of Microarray Gene Expression Data
Gene expression profiling methods (Total RNA isolation and microarray processing) are available in Supplementary Methods.
Murine drug treatment studies
Genetically engineered mice harboring a conditional activating mutation (G12D) at the endogenous Kras locus, conditional Lkb1 knockout, and conditional p53 knockout have been described previously (21, 23) . All animal treatment studies were reviewed and approved by the IACUC at the Dana-Farber Cancer Institute. Kras and Kras/Lkb1 mice were treated with 5 × 10 6 p.f.u. adeno-Cre (University of Iowa viral vector core) intranasally as previously described (20, 21, 23) , and subjected to magnetic resonance imaging (MRI) to document tumor burden. After initial imaging, animals were subjected to treatment with JQ1 formulated in 10%DMSO, 90% 10%-Hyroxypropyl Beta Cyclodextrin and given IP route at 50 mg/kg or vehicle daily. Primary lung tumors were macrodissected and formalin fixed or frozen in liquid nitrogen and stored at −80°C until use.
Imaging with tumor volume measurement and immunohistochemistry
MRI measurements were performed as previously described (20) , to determine the reduction in tumor volume after the indicated time of treatment. Using the RARE sequence scans, tumor volume measurements were generated using in-house custom software. 3D Slicer was used to reconstruct MRI volumetric measurements as reported previously (20) . All murine FDG-PET/CT studies were performed with a preclinical small animal PET/CT system (Siemens Inveon) after injection with 14MBq of 18F-FDG as previously reported (20) . Immunohistochemistry was performed as described previously (20) . Details and a list of antibodies used is available in the Supplementary Methods.
Statistical analysis
Unless otherwise stated, comparisons of statistical significance were performed using the Student's t-test. A p-value < 0.05 was considered statistically significant.
RESULTS

JQ1 is active in NSCLC cells of different genotypes, but concomitant alteration of
KRAS and LKB1 confers resistance
To evaluate the efficacy of BET bromodomain inhibition in NSCLC, human cell lines bearing mutations in KRAS were first screened for sensitivity to the prototype BET inhibitor, JQ1. Unlike hematologic malignancies, where uniform activity of JQ1 is observed, 24 NSCLC cell lines displayed clear dose-dependent sensitivity or resistance to bromodomain inhibition ( Supplementary Fig. 1A and 1B). Anti-proliferative activity of BET inhibition was observed in all genetically-defined subtypes of NSCLC, but closer inspection of common genetic alterations revealed reduced efficacy when LKB1 and KRAS were both altered ( Fig. 2B ).
Interestingly, exposure to JQ1 also promoted accumulation of BRD4 in cellular lysates within 2 hours (Supplementary Fig. 2B ). As BRD4 and MYC primarily localize to the nucleus, we examined the compartment-specific enrichment of BRD4 and MYC in H441 cells upon JQ1 treatment (Fig. 2C) . In H441 cells, JQ1 treatment promoted increased appearance of BRD4 in the cytosol and depletion of MYC in the nucleus, illustrating the effect of JQ1 on BET bromodomain displacement from chromatin and corroborating the marked effect on MYC expression.
BRD4 knockdown in H441 cells recapitulates effects of JQ1 in H441 cells
To understand the mechanism of MYC transcriptional inhibition, we assessed function of BET bromodomain proteins in enforcing MYC expression. H441 and A549 cells were transduced with two lentiviral shRNA vectors designed to target BRD4 or a control (non-target) shRNA, followed by puromycin selection. Within 96 hours post lentiviral transduction, BRD4 was significantly (>80%) depleted ( vehicle treated samples. Effects on MYC-specific transcription were investigated using reported, functionally validated gene signatures correlating with deregulated MYC (15, 16, 25, 26) . All MYC signatures were strongly correlated with downregulation of gene expression by JQ1 in NCI-H441 cells (Fig. 3A) . To ascertain whether the H441 cells are MYC dependent, we depleted MYC using lentiviral shRNA (Fig. 3B) 
induction of markers of late apoptosis, cleaved PARP and cleaved caspase 3 (Fig. 4B) .
The A549 cells transduced with vector control failed to undergo programmed cell death, compared to untreated controls (Fig. 4B) .
Efficacy of BET bromodomain inhibition in GEM models of KRAS mutated NSCLC
Having demonstrated that a subset of NSCLC cells harboring mutant KRAS are dependent on the BRD4-MYC transcriptional axis, we next explored the therapeutic relevance of BET bromodomain inhibition using genetically engineered mice (GEM) with either mutant kras or mutant kras/lkb1. Activation of mutant kras (G12D) and inactivation of lkb1 in the lung epithelium was initiated using nasal instillation of adenovirus encoding the CRE recombinase. Mice with established tumors, defined by evident and significant tumor burden by magnetic resonance imaging (MRI), were treated with 50 mg/kg JQ1 or vehicle control by intraperitoneal injection. Response to treatment was monitored by serial MRI imaging (Fig. 5A) . Tumor volume in response to therapy was determined by previously validated, quantitative methods (20) . Among mice with kras mutant tumors, single agent JQ1 provoked a partial response in 100 % of treated animals, defined by a greater than 30 % reduction in tumor volume (Fig. 5A and 
Histologic confirmation of radiographic responses to JQ1 treatment in mutant kras mice
To confirm the radiographic responses in kras mice, we performed a detailed immunohistochemical examination of tumor tissue isolated from treated animals. For these pharmacodynamic studies, mice were treated with three daily doses of vehicle or JQ1 prior to sacrifice and harvest of tumors for immunohistochemical analysis. In kras mice, JQ1 treatment resulted in increased staining for brd4 decreased staining for myc (Fig. 5D, left) . In contrast, JQ1 treatment failed to deplete myc in mutant kras/lkb1 mice (Fig. 5D , right) while brd4 staining increased upon JQ1 treatment, consistent with our human cell line data ( Fig. 2A) . To confirm myc depletion in mutant Kras mice, total RNA was isolated from both JQ1 treated and vehicle treated tumor nodules and evaluated by real time PCR using probes specific to murine myc (Fig.5E ). Pharmacologic The results with BRD4 knockdown (Fig. 2D and E) and MYC knockdown ( viability and increased apoptosis. In contrast, JQ1 treatment in KRAS/LKB1 mutant cells does not promote the depletion of MYC (Fig. 2B) . Similarly, the depletion of BRD4 in A549 cells did not result in the depletion of MYC (Fig. 2D) , suggesting, but not proving, that the interactions between BRD4 and MYC in KRAS/LKB1 mutant cells are distinct from those in KRAS mutant cells.
Previously, we have reported that murine tumors with both kras and lkb1 mutations are highly metastatic and respond poorly to simultaneous inhibition of PI3K
and MAPK pathways (6, 21) . This observation suggests that LKB1 deletion impacts how mutant KRAS regulates PI3K and MAPK pathway activity. The differential activation of the PI3K and MAPK pathways by mutant KRAS in the absence of LKB1 might also promote cellular independence from MYC transcriptional activity, as PI3K and MAPK signaling activities have been shown to control MYC turnover (7, 9) .
Ongoing research in our laboratory using genome-wide chromatin immunoprecipitation will explore differential enhancer structure and function in the MYC gene desert.
Of note, murine NSCLC tumors harboring mutant kras were sensitive to BET bromodomain inhibition; however, not all human mutant KRAS NSCLC cell lines are sensitive to the inhibition. The discrepancy in the response to JQ1 may be due to the fact that the genetically engineered mouse model used in this study is kras-driven while not all human NSCLC cell lines harboring mutant KRAS are driven by mutant KRAS as reported previously (3, 4, 24, 27) BET bromodomain inhibition on MYC-driven NSCLC cells with or without mutant KRAS will provide more mechanistic insights.
To confirm that mutational status of LKB1 determines the antitumoral activity of JQ1 in NSCLC harboring mutant KRAS, we generated a set of isogenic cell lines where LKB1 was restored (in mutated resistant cells) or enforced (in wild-type sensitive cells; Fig. 4 ). Together these studies confirmed the pronounced effect of LKB1 status on JQ1 sensitivity and JQ1-dependent MYC downregulation.
While these studies were being completed, Lockwood et al. reported the suppression of the oncogenic transcription factor FOSL1 by BET bromodomain inhibition, also using the JQ1 chemical probe from the Bradner laboratory (28) . To confirm these observations, we treated JQ1 sensitive NCI-H441 with dose-ranging JQ1 for 48 hours (Supplementary Fig. 3A ). Whole cell lysates were subjected to Western blot using MYC and FOSL1 antibodies. We observed dose-dependent depletion of MYC and FOSL1, though MYC exhibited comparatively increased sensitivity to BET inhibition.
To explore whether FOSL1 depletion by JQ1 explains the differential responses to JQ1 in mutant KRAS NSCLC cell lines with or without LKB1, whole cell lysates from isogenic paired cell lines treated with JQ1 or DMSO were subjected to immunoblot for FOSL1 ( Supplementary Fig. 3B ). In the paired H441 cell lines, the depletion of FOSL1 by JQ1 treatment did not differ between LKB1 expressing and deficient cells. In the 
differential effect of JQ1 in LKB1 deficient and proficient NSCLC cell lines harboring KRAS mutation. In vivo, JQ1 treatment did not promote fosl1 transcript depletion in murine mutant kras tumors (Data not shown). Further collaborative research will help to contextualize effects on these two BET-responsive master regulatory transcription factors.
Interestingly, the exposure to JQ1 promoted nuclear accumulation of BRD4 in all the NSCLC cell lines tested ( Fig. 2A and 2C) . The rapid increase in BRD4 staining by immunoblot ( Supplementary Fig. 2B ) may relate to competitive binding of JQ1 with chromatin, consistent with increased free BRD4 that could have significance for pharmacodynamic biomarker development. 
